nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—NFKB1—type 2 diabetes mellitus	0.215	0.523	CbGaD
Thalidomide—TNF—type 2 diabetes mellitus	0.0658	0.16	CbGaD
Thalidomide—CYP2E1—type 2 diabetes mellitus	0.0507	0.123	CbGaD
Thalidomide—CYP1A2—type 2 diabetes mellitus	0.0482	0.117	CbGaD
Thalidomide—PTGS2—type 2 diabetes mellitus	0.0312	0.0761	CbGaD
Thalidomide—PTGS1—Chlorpropamide—type 2 diabetes mellitus	0.0243	0.0731	CbGbCtD
Thalidomide—PTGS1—Pioglitazone—type 2 diabetes mellitus	0.0243	0.0731	CbGbCtD
Thalidomide—PTGS1—Rosiglitazone—type 2 diabetes mellitus	0.0224	0.0675	CbGbCtD
Thalidomide—PTGS1—Nateglinide—type 2 diabetes mellitus	0.0184	0.0554	CbGbCtD
Thalidomide—PTGS1—Irbesartan—type 2 diabetes mellitus	0.0176	0.0531	CbGbCtD
Thalidomide—CYP2C19—Gliclazide—type 2 diabetes mellitus	0.0138	0.0416	CbGbCtD
Thalidomide—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.0135	0.0407	CbGbCtD
Thalidomide—CYP2C9—Glipizide—type 2 diabetes mellitus	0.0124	0.0372	CbGbCtD
Thalidomide—CYP2C19—Pioglitazone—type 2 diabetes mellitus	0.0118	0.0354	CbGbCtD
Thalidomide—CYP2C19—Chlorpropamide—type 2 diabetes mellitus	0.0118	0.0354	CbGbCtD
Thalidomide—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.0115	0.0346	CbGbCtD
Thalidomide—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.011	0.0333	CbGbCtD
Thalidomide—CYP2C19—Rosiglitazone—type 2 diabetes mellitus	0.0108	0.0327	CbGbCtD
Thalidomide—CYP2C19—Tolbutamide—type 2 diabetes mellitus	0.0105	0.0315	CbGbCtD
Thalidomide—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.01	0.0301	CbGbCtD
Thalidomide—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.00977	0.0294	CbGbCtD
Thalidomide—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.00977	0.0294	CbGbCtD
Thalidomide—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.00902	0.0272	CbGbCtD
Thalidomide—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.00871	0.0262	CbGbCtD
Thalidomide—CYP2C9—Valsartan—type 2 diabetes mellitus	0.00796	0.024	CbGbCtD
Thalidomide—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.00788	0.0237	CbGbCtD
Thalidomide—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00745	0.0224	CbGbCtD
Thalidomide—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.0074	0.0223	CbGbCtD
Thalidomide—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.0071	0.0214	CbGbCtD
Thalidomide—CYP3A5—Losartan—type 2 diabetes mellitus	0.00682	0.0205	CbGbCtD
Thalidomide—CYP2C19—Glyburide—type 2 diabetes mellitus	0.00602	0.0181	CbGbCtD
Thalidomide—CYP2C19—Losartan—type 2 diabetes mellitus	0.0055	0.0166	CbGbCtD
Thalidomide—CYP1A2—Losartan—type 2 diabetes mellitus	0.00508	0.0153	CbGbCtD
Thalidomide—CYP2C9—Glyburide—type 2 diabetes mellitus	0.005	0.0151	CbGbCtD
Thalidomide—CYP2C9—Losartan—type 2 diabetes mellitus	0.00457	0.0138	CbGbCtD
Thalidomide—Menadione—F7—type 2 diabetes mellitus	0.00137	0.398	CrCbGaD
Thalidomide—NFKB1—islet of Langerhans—type 2 diabetes mellitus	0.00121	0.054	CbGeAlD
Thalidomide—PTGS2—leg—type 2 diabetes mellitus	0.00105	0.0468	CbGeAlD
Thalidomide—CRBN—islet of Langerhans—type 2 diabetes mellitus	0.00101	0.0453	CbGeAlD
Thalidomide—PTGS2—hindlimb—type 2 diabetes mellitus	0.000938	0.0418	CbGeAlD
Thalidomide—NFKB1—cardiovascular system—type 2 diabetes mellitus	0.000876	0.039	CbGeAlD
Thalidomide—CRBN—retina—type 2 diabetes mellitus	0.000868	0.0387	CbGeAlD
Thalidomide—NFKB1—kidney—type 2 diabetes mellitus	0.000857	0.0382	CbGeAlD
Thalidomide—NFKB1—cortex of kidney—type 2 diabetes mellitus	0.000834	0.0372	CbGeAlD
Thalidomide—CRBN—nephron tubule—type 2 diabetes mellitus	0.000817	0.0364	CbGeAlD
Thalidomide—NFKB1—adipose tissue—type 2 diabetes mellitus	0.000772	0.0344	CbGeAlD
Thalidomide—CRBN—pancreas—type 2 diabetes mellitus	0.000713	0.0318	CbGeAlD
Thalidomide—CRBN—cortex of kidney—type 2 diabetes mellitus	0.000699	0.0312	CbGeAlD
Thalidomide—FGFR2—cardiovascular system—type 2 diabetes mellitus	0.000658	0.0293	CbGeAlD
Thalidomide—CRBN—adipose tissue—type 2 diabetes mellitus	0.000647	0.0289	CbGeAlD
Thalidomide—FGFR2—kidney—type 2 diabetes mellitus	0.000643	0.0287	CbGeAlD
Thalidomide—PTGS1—artery—type 2 diabetes mellitus	0.000602	0.0268	CbGeAlD
Thalidomide—FGFR2—adipose tissue—type 2 diabetes mellitus	0.00058	0.0259	CbGeAlD
Thalidomide—PTGS2—artery—type 2 diabetes mellitus	0.000575	0.0256	CbGeAlD
Thalidomide—NFKB1—liver—type 2 diabetes mellitus	0.000541	0.0241	CbGeAlD
Thalidomide—PTGS1—endothelium—type 2 diabetes mellitus	0.000508	0.0227	CbGeAlD
Thalidomide—PTGS2—endothelium—type 2 diabetes mellitus	0.000486	0.0217	CbGeAlD
Thalidomide—Pomalidomide—TNF—type 2 diabetes mellitus	0.000462	0.134	CrCbGaD
Thalidomide—CRBN—liver—type 2 diabetes mellitus	0.000454	0.0202	CbGeAlD
Thalidomide—FGFR2—liver—type 2 diabetes mellitus	0.000407	0.0181	CbGeAlD
Thalidomide—Pomalidomide—CYP1A2—type 2 diabetes mellitus	0.000338	0.0985	CrCbGaD
Thalidomide—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	0.000322	0.0143	CbGeAlD
Thalidomide—PTGS2—islet of Langerhans—type 2 diabetes mellitus	0.000276	0.0123	CbGeAlD
Thalidomide—Menadione—MTHFR—type 2 diabetes mellitus	0.000269	0.0782	CrCbGaD
Thalidomide—CYP3A5—nephron tubule—type 2 diabetes mellitus	0.000259	0.0116	CbGeAlD
Thalidomide—CYP2E1—nephron tubule—type 2 diabetes mellitus	0.000242	0.0108	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—type 2 diabetes mellitus	0.000236	0.0687	CrCbGaD
Thalidomide—CYP1A1—kidney—type 2 diabetes mellitus	0.000233	0.0104	CbGeAlD
Thalidomide—CYP2C9—cardiovascular system—type 2 diabetes mellitus	0.000229	0.0102	CbGeAlD
Thalidomide—CYP3A5—kidney—type 2 diabetes mellitus	0.000228	0.0102	CbGeAlD
Thalidomide—CYP3A5—pancreas—type 2 diabetes mellitus	0.000226	0.0101	CbGeAlD
Thalidomide—Pomalidomide—CYP3A4—type 2 diabetes mellitus	0.000224	0.0652	CrCbGaD
Thalidomide—CYP3A5—cortex of kidney—type 2 diabetes mellitus	0.000222	0.00989	CbGeAlD
Thalidomide—Pomalidomide—PTGS2—type 2 diabetes mellitus	0.000219	0.0639	CrCbGaD
Thalidomide—CYP2E1—cardiovascular system—type 2 diabetes mellitus	0.000217	0.00968	CbGeAlD
Thalidomide—CYP2E1—kidney—type 2 diabetes mellitus	0.000212	0.00947	CbGeAlD
Thalidomide—CYP1A1—adipose tissue—type 2 diabetes mellitus	0.00021	0.00936	CbGeAlD
Thalidomide—PTGS1—cardiovascular system—type 2 diabetes mellitus	0.000209	0.00932	CbGeAlD
Thalidomide—CYP2E1—cortex of kidney—type 2 diabetes mellitus	0.000207	0.00922	CbGeAlD
Thalidomide—CYP3A5—adipose tissue—type 2 diabetes mellitus	0.000205	0.00915	CbGeAlD
Thalidomide—PTGS1—kidney—type 2 diabetes mellitus	0.000205	0.00912	CbGeAlD
Thalidomide—PTGS2—cardiovascular system—type 2 diabetes mellitus	0.0002	0.00891	CbGeAlD
Thalidomide—PTGS2—kidney—type 2 diabetes mellitus	0.000196	0.00872	CbGeAlD
Thalidomide—PTGS2—pancreas—type 2 diabetes mellitus	0.000194	0.00866	CbGeAlD
Thalidomide—PTGS1—adipose tissue—type 2 diabetes mellitus	0.000184	0.00822	CbGeAlD
Thalidomide—CYP2C19—liver—type 2 diabetes mellitus	0.000183	0.00815	CbGeAlD
Thalidomide—PTGS2—adipose tissue—type 2 diabetes mellitus	0.000176	0.00786	CbGeAlD
Thalidomide—Menadione—CYP2E1—type 2 diabetes mellitus	0.000163	0.0476	CrCbGaD
Thalidomide—Menadione—CYP1A2—type 2 diabetes mellitus	0.000155	0.0452	CrCbGaD
Thalidomide—CYP1A2—liver—type 2 diabetes mellitus	0.000149	0.00665	CbGeAlD
Thalidomide—CYP1A1—liver—type 2 diabetes mellitus	0.000147	0.00656	CbGeAlD
Thalidomide—CYP3A5—liver—type 2 diabetes mellitus	0.000144	0.00642	CbGeAlD
Thalidomide—CYP2C9—liver—type 2 diabetes mellitus	0.000142	0.00632	CbGeAlD
Thalidomide—CYP2E1—liver—type 2 diabetes mellitus	0.000134	0.00599	CbGeAlD
Thalidomide—PTGS2—liver—type 2 diabetes mellitus	0.000124	0.00551	CbGeAlD
Thalidomide—Anxiety—Irbesartan—type 2 diabetes mellitus	3.73e-05	0.000275	CcSEcCtD
Thalidomide—Hypersensitivity—Glyburide—type 2 diabetes mellitus	3.73e-05	0.000274	CcSEcCtD
Thalidomide—Nervous system disorder—Metformin—type 2 diabetes mellitus	3.73e-05	0.000274	CcSEcCtD
Thalidomide—Thrombocytopenia—Metformin—type 2 diabetes mellitus	3.72e-05	0.000274	CcSEcCtD
Thalidomide—Dyspnoea—Valsartan—type 2 diabetes mellitus	3.72e-05	0.000274	CcSEcCtD
Thalidomide—Vertigo—Losartan—type 2 diabetes mellitus	3.72e-05	0.000274	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	3.72e-05	0.000274	CcSEcCtD
Thalidomide—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	3.72e-05	0.000274	CcSEcCtD
Thalidomide—Somnolence—Valsartan—type 2 diabetes mellitus	3.71e-05	0.000273	CcSEcCtD
Thalidomide—Syncope—Losartan—type 2 diabetes mellitus	3.71e-05	0.000273	CcSEcCtD
Thalidomide—Paraesthesia—Orlistat—type 2 diabetes mellitus	3.71e-05	0.000273	CcSEcCtD
Thalidomide—Leukopenia—Losartan—type 2 diabetes mellitus	3.71e-05	0.000273	CcSEcCtD
Thalidomide—Discomfort—Irbesartan—type 2 diabetes mellitus	3.7e-05	0.000272	CcSEcCtD
Thalidomide—Skin disorder—Metformin—type 2 diabetes mellitus	3.7e-05	0.000272	CcSEcCtD
Thalidomide—Immune system disorder—Ramipril—type 2 diabetes mellitus	3.68e-05	0.000271	CcSEcCtD
Thalidomide—Hyperhidrosis—Metformin—type 2 diabetes mellitus	3.68e-05	0.000271	CcSEcCtD
Thalidomide—Dyspepsia—Valsartan—type 2 diabetes mellitus	3.68e-05	0.000271	CcSEcCtD
Thalidomide—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	3.68e-05	0.00027	CcSEcCtD
Thalidomide—Dizziness—Bromocriptine—type 2 diabetes mellitus	3.66e-05	0.000269	CcSEcCtD
Thalidomide—Dry mouth—Irbesartan—type 2 diabetes mellitus	3.66e-05	0.000269	CcSEcCtD
Thalidomide—Palpitations—Losartan—type 2 diabetes mellitus	3.66e-05	0.000269	CcSEcCtD
Thalidomide—Nausea—Glimepiride—type 2 diabetes mellitus	3.65e-05	0.000268	CcSEcCtD
Thalidomide—Arrhythmia—Ramipril—type 2 diabetes mellitus	3.64e-05	0.000268	CcSEcCtD
Thalidomide—Loss of consciousness—Losartan—type 2 diabetes mellitus	3.64e-05	0.000268	CcSEcCtD
Thalidomide—Nausea—Sitagliptin—type 2 diabetes mellitus	3.64e-05	0.000267	CcSEcCtD
Thalidomide—Dyspepsia—Orlistat—type 2 diabetes mellitus	3.63e-05	0.000267	CcSEcCtD
Thalidomide—Asthenia—Glyburide—type 2 diabetes mellitus	3.63e-05	0.000267	CcSEcCtD
Thalidomide—Decreased appetite—Valsartan—type 2 diabetes mellitus	3.63e-05	0.000267	CcSEcCtD
Thalidomide—Anorexia—Metformin—type 2 diabetes mellitus	3.63e-05	0.000267	CcSEcCtD
Thalidomide—Cough—Losartan—type 2 diabetes mellitus	3.61e-05	0.000266	CcSEcCtD
Thalidomide—Urticaria—Gliclazide—type 2 diabetes mellitus	3.61e-05	0.000266	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	3.61e-05	0.000265	CcSEcCtD
Thalidomide—Alopecia—Ramipril—type 2 diabetes mellitus	3.6e-05	0.000265	CcSEcCtD
Thalidomide—Fatigue—Valsartan—type 2 diabetes mellitus	3.6e-05	0.000265	CcSEcCtD
Thalidomide—Body temperature increased—Gliclazide—type 2 diabetes mellitus	3.59e-05	0.000264	CcSEcCtD
Thalidomide—Abdominal pain—Gliclazide—type 2 diabetes mellitus	3.59e-05	0.000264	CcSEcCtD
Thalidomide—Oedema—Irbesartan—type 2 diabetes mellitus	3.59e-05	0.000264	CcSEcCtD
Thalidomide—Decreased appetite—Orlistat—type 2 diabetes mellitus	3.59e-05	0.000264	CcSEcCtD
Thalidomide—Pruritus—Glyburide—type 2 diabetes mellitus	3.58e-05	0.000264	CcSEcCtD
Thalidomide—Mental disorder—Ramipril—type 2 diabetes mellitus	3.57e-05	0.000263	CcSEcCtD
Thalidomide—Constipation—Valsartan—type 2 diabetes mellitus	3.57e-05	0.000263	CcSEcCtD
Thalidomide—Infection—Irbesartan—type 2 diabetes mellitus	3.57e-05	0.000262	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	3.56e-05	0.000262	CcSEcCtD
Thalidomide—Fatigue—Orlistat—type 2 diabetes mellitus	3.56e-05	0.000262	CcSEcCtD
Thalidomide—Hypotension—Metformin—type 2 diabetes mellitus	3.56e-05	0.000261	CcSEcCtD
Thalidomide—Malnutrition—Ramipril—type 2 diabetes mellitus	3.55e-05	0.000261	CcSEcCtD
Thalidomide—Shock—Irbesartan—type 2 diabetes mellitus	3.53e-05	0.00026	CcSEcCtD
Thalidomide—Pain—Orlistat—type 2 diabetes mellitus	3.53e-05	0.00026	CcSEcCtD
Thalidomide—Arthralgia—Losartan—type 2 diabetes mellitus	3.52e-05	0.000259	CcSEcCtD
Thalidomide—Chest pain—Losartan—type 2 diabetes mellitus	3.52e-05	0.000259	CcSEcCtD
Thalidomide—Myalgia—Losartan—type 2 diabetes mellitus	3.52e-05	0.000259	CcSEcCtD
Thalidomide—Vomiting—Bromocriptine—type 2 diabetes mellitus	3.52e-05	0.000259	CcSEcCtD
Thalidomide—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	3.52e-05	0.000259	CcSEcCtD
Thalidomide—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	3.52e-05	0.000259	CcSEcCtD
Thalidomide—Anxiety—Losartan—type 2 diabetes mellitus	3.51e-05	0.000258	CcSEcCtD
Thalidomide—Tachycardia—Irbesartan—type 2 diabetes mellitus	3.5e-05	0.000258	CcSEcCtD
Thalidomide—Rash—Bromocriptine—type 2 diabetes mellitus	3.49e-05	0.000257	CcSEcCtD
Thalidomide—Dermatitis—Bromocriptine—type 2 diabetes mellitus	3.49e-05	0.000257	CcSEcCtD
Thalidomide—Skin disorder—Irbesartan—type 2 diabetes mellitus	3.49e-05	0.000257	CcSEcCtD
Thalidomide—Tension—Ramipril—type 2 diabetes mellitus	3.48e-05	0.000256	CcSEcCtD
Thalidomide—Discomfort—Losartan—type 2 diabetes mellitus	3.48e-05	0.000256	CcSEcCtD
Thalidomide—Dysgeusia—Ramipril—type 2 diabetes mellitus	3.48e-05	0.000256	CcSEcCtD
Thalidomide—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	3.47e-05	0.000255	CcSEcCtD
Thalidomide—Headache—Bromocriptine—type 2 diabetes mellitus	3.47e-05	0.000255	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	3.47e-05	0.000255	CcSEcCtD
Thalidomide—Diarrhoea—Glyburide—type 2 diabetes mellitus	3.46e-05	0.000255	CcSEcCtD
Thalidomide—Nervousness—Ramipril—type 2 diabetes mellitus	3.45e-05	0.000254	CcSEcCtD
Thalidomide—Dry mouth—Losartan—type 2 diabetes mellitus	3.45e-05	0.000254	CcSEcCtD
Thalidomide—Anorexia—Irbesartan—type 2 diabetes mellitus	3.42e-05	0.000252	CcSEcCtD
Thalidomide—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	3.42e-05	0.000251	CcSEcCtD
Thalidomide—Paraesthesia—Metformin—type 2 diabetes mellitus	3.42e-05	0.000251	CcSEcCtD
Thalidomide—Muscle spasms—Ramipril—type 2 diabetes mellitus	3.41e-05	0.000251	CcSEcCtD
Thalidomide—Confusional state—Losartan—type 2 diabetes mellitus	3.41e-05	0.000251	CcSEcCtD
Thalidomide—Feeling abnormal—Orlistat—type 2 diabetes mellitus	3.4e-05	0.00025	CcSEcCtD
Thalidomide—Dyspnoea—Metformin—type 2 diabetes mellitus	3.39e-05	0.000249	CcSEcCtD
Thalidomide—Somnolence—Metformin—type 2 diabetes mellitus	3.38e-05	0.000249	CcSEcCtD
Thalidomide—Oedema—Losartan—type 2 diabetes mellitus	3.38e-05	0.000249	CcSEcCtD
Thalidomide—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	3.38e-05	0.000248	CcSEcCtD
Thalidomide—Infection—Losartan—type 2 diabetes mellitus	3.36e-05	0.000247	CcSEcCtD
Thalidomide—Hypotension—Irbesartan—type 2 diabetes mellitus	3.35e-05	0.000247	CcSEcCtD
Thalidomide—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	3.35e-05	0.000246	CcSEcCtD
Thalidomide—Dyspepsia—Metformin—type 2 diabetes mellitus	3.35e-05	0.000246	CcSEcCtD
Thalidomide—Tremor—Ramipril—type 2 diabetes mellitus	3.33e-05	0.000245	CcSEcCtD
Thalidomide—Shock—Losartan—type 2 diabetes mellitus	3.32e-05	0.000245	CcSEcCtD
Thalidomide—Urticaria—Valsartan—type 2 diabetes mellitus	3.32e-05	0.000244	CcSEcCtD
Thalidomide—Nervous system disorder—Losartan—type 2 diabetes mellitus	3.31e-05	0.000244	CcSEcCtD
Thalidomide—Thrombocytopenia—Losartan—type 2 diabetes mellitus	3.31e-05	0.000243	CcSEcCtD
Thalidomide—Decreased appetite—Metformin—type 2 diabetes mellitus	3.31e-05	0.000243	CcSEcCtD
Thalidomide—Abdominal pain—Valsartan—type 2 diabetes mellitus	3.3e-05	0.000243	CcSEcCtD
Thalidomide—Tachycardia—Losartan—type 2 diabetes mellitus	3.3e-05	0.000243	CcSEcCtD
Thalidomide—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	3.29e-05	0.000242	CcSEcCtD
Thalidomide—Nausea—Bromocriptine—type 2 diabetes mellitus	3.29e-05	0.000242	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	3.28e-05	0.000242	CcSEcCtD
Thalidomide—Fatigue—Metformin—type 2 diabetes mellitus	3.28e-05	0.000241	CcSEcCtD
Thalidomide—Urticaria—Orlistat—type 2 diabetes mellitus	3.28e-05	0.000241	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	3.27e-05	0.000241	CcSEcCtD
Thalidomide—Hyperhidrosis—Losartan—type 2 diabetes mellitus	3.27e-05	0.00024	CcSEcCtD
Thalidomide—Abdominal pain—Orlistat—type 2 diabetes mellitus	3.26e-05	0.00024	CcSEcCtD
Thalidomide—Body temperature increased—Orlistat—type 2 diabetes mellitus	3.26e-05	0.00024	CcSEcCtD
Thalidomide—Asthenia—Gliclazide—type 2 diabetes mellitus	3.26e-05	0.00024	CcSEcCtD
Thalidomide—Agitation—Ramipril—type 2 diabetes mellitus	3.26e-05	0.00024	CcSEcCtD
Thalidomide—Constipation—Metformin—type 2 diabetes mellitus	3.25e-05	0.000239	CcSEcCtD
Thalidomide—Angioedema—Ramipril—type 2 diabetes mellitus	3.24e-05	0.000239	CcSEcCtD
Thalidomide—Paraesthesia—Irbesartan—type 2 diabetes mellitus	3.22e-05	0.000237	CcSEcCtD
Thalidomide—Anorexia—Losartan—type 2 diabetes mellitus	3.22e-05	0.000237	CcSEcCtD
Thalidomide—Vomiting—Glyburide—type 2 diabetes mellitus	3.22e-05	0.000237	CcSEcCtD
Thalidomide—Pruritus—Gliclazide—type 2 diabetes mellitus	3.22e-05	0.000237	CcSEcCtD
Thalidomide—Malaise—Ramipril—type 2 diabetes mellitus	3.2e-05	0.000235	CcSEcCtD
Thalidomide—Dyspnoea—Irbesartan—type 2 diabetes mellitus	3.2e-05	0.000235	CcSEcCtD
Thalidomide—Rash—Glyburide—type 2 diabetes mellitus	3.19e-05	0.000235	CcSEcCtD
Thalidomide—Somnolence—Irbesartan—type 2 diabetes mellitus	3.19e-05	0.000235	CcSEcCtD
Thalidomide—Dermatitis—Glyburide—type 2 diabetes mellitus	3.19e-05	0.000235	CcSEcCtD
Thalidomide—Vertigo—Ramipril—type 2 diabetes mellitus	3.19e-05	0.000235	CcSEcCtD
Thalidomide—Syncope—Ramipril—type 2 diabetes mellitus	3.18e-05	0.000234	CcSEcCtD
Thalidomide—Leukopenia—Ramipril—type 2 diabetes mellitus	3.18e-05	0.000234	CcSEcCtD
Thalidomide—Headache—Glyburide—type 2 diabetes mellitus	3.17e-05	0.000233	CcSEcCtD
Thalidomide—Dyspepsia—Irbesartan—type 2 diabetes mellitus	3.16e-05	0.000232	CcSEcCtD
Thalidomide—Hypotension—Losartan—type 2 diabetes mellitus	3.16e-05	0.000232	CcSEcCtD
Thalidomide—Palpitations—Ramipril—type 2 diabetes mellitus	3.14e-05	0.000231	CcSEcCtD
Thalidomide—Feeling abnormal—Metformin—type 2 diabetes mellitus	3.14e-05	0.000231	CcSEcCtD
Thalidomide—Decreased appetite—Irbesartan—type 2 diabetes mellitus	3.12e-05	0.00023	CcSEcCtD
Thalidomide—Loss of consciousness—Ramipril—type 2 diabetes mellitus	3.12e-05	0.000229	CcSEcCtD
Thalidomide—Diarrhoea—Gliclazide—type 2 diabetes mellitus	3.11e-05	0.000229	CcSEcCtD
Thalidomide—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	3.11e-05	0.000229	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	3.1e-05	0.000228	CcSEcCtD
Thalidomide—Cough—Ramipril—type 2 diabetes mellitus	3.1e-05	0.000228	CcSEcCtD
Thalidomide—Fatigue—Irbesartan—type 2 diabetes mellitus	3.1e-05	0.000228	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	3.08e-05	0.000226	CcSEcCtD
Thalidomide—Hypersensitivity—Valsartan—type 2 diabetes mellitus	3.08e-05	0.000226	CcSEcCtD
Thalidomide—Convulsion—Ramipril—type 2 diabetes mellitus	3.08e-05	0.000226	CcSEcCtD
Thalidomide—Pain—Irbesartan—type 2 diabetes mellitus	3.07e-05	0.000226	CcSEcCtD
Thalidomide—Constipation—Irbesartan—type 2 diabetes mellitus	3.07e-05	0.000226	CcSEcCtD
Thalidomide—Insomnia—Losartan—type 2 diabetes mellitus	3.06e-05	0.000225	CcSEcCtD
Thalidomide—Hypersensitivity—Orlistat—type 2 diabetes mellitus	3.04e-05	0.000224	CcSEcCtD
Thalidomide—Paraesthesia—Losartan—type 2 diabetes mellitus	3.03e-05	0.000223	CcSEcCtD
Thalidomide—Urticaria—Metformin—type 2 diabetes mellitus	3.02e-05	0.000222	CcSEcCtD
Thalidomide—Arthralgia—Ramipril—type 2 diabetes mellitus	3.02e-05	0.000222	CcSEcCtD
Thalidomide—Myalgia—Ramipril—type 2 diabetes mellitus	3.02e-05	0.000222	CcSEcCtD
Thalidomide—Chest pain—Ramipril—type 2 diabetes mellitus	3.02e-05	0.000222	CcSEcCtD
Thalidomide—Dyspnoea—Losartan—type 2 diabetes mellitus	3.01e-05	0.000222	CcSEcCtD
Thalidomide—Anxiety—Ramipril—type 2 diabetes mellitus	3.01e-05	0.000222	CcSEcCtD
Thalidomide—Nausea—Glyburide—type 2 diabetes mellitus	3.01e-05	0.000221	CcSEcCtD
Thalidomide—Abdominal pain—Metformin—type 2 diabetes mellitus	3.01e-05	0.000221	CcSEcCtD
Thalidomide—Dizziness—Gliclazide—type 2 diabetes mellitus	3.01e-05	0.000221	CcSEcCtD
Thalidomide—Somnolence—Losartan—type 2 diabetes mellitus	3e-05	0.000221	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	3e-05	0.000221	CcSEcCtD
Thalidomide—Asthenia—Valsartan—type 2 diabetes mellitus	3e-05	0.00022	CcSEcCtD
Thalidomide—Discomfort—Ramipril—type 2 diabetes mellitus	2.99e-05	0.00022	CcSEcCtD
Thalidomide—Dyspepsia—Losartan—type 2 diabetes mellitus	2.97e-05	0.000219	CcSEcCtD
Thalidomide—Asthenia—Orlistat—type 2 diabetes mellitus	2.96e-05	0.000218	CcSEcCtD
Thalidomide—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	2.96e-05	0.000218	CcSEcCtD
Thalidomide—Pruritus—Valsartan—type 2 diabetes mellitus	2.96e-05	0.000217	CcSEcCtD
Thalidomide—Dry mouth—Ramipril—type 2 diabetes mellitus	2.96e-05	0.000217	CcSEcCtD
Thalidomide—Decreased appetite—Losartan—type 2 diabetes mellitus	2.94e-05	0.000216	CcSEcCtD
Thalidomide—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	2.94e-05	0.000216	CcSEcCtD
Thalidomide—Confusional state—Ramipril—type 2 diabetes mellitus	2.92e-05	0.000215	CcSEcCtD
Thalidomide—Pruritus—Orlistat—type 2 diabetes mellitus	2.92e-05	0.000215	CcSEcCtD
Thalidomide—Fatigue—Losartan—type 2 diabetes mellitus	2.91e-05	0.000214	CcSEcCtD
Thalidomide—Oedema—Ramipril—type 2 diabetes mellitus	2.9e-05	0.000213	CcSEcCtD
Thalidomide—Vomiting—Gliclazide—type 2 diabetes mellitus	2.89e-05	0.000213	CcSEcCtD
Thalidomide—Pain—Losartan—type 2 diabetes mellitus	2.89e-05	0.000213	CcSEcCtD
Thalidomide—Constipation—Losartan—type 2 diabetes mellitus	2.89e-05	0.000213	CcSEcCtD
Thalidomide—Rash—Gliclazide—type 2 diabetes mellitus	2.87e-05	0.000211	CcSEcCtD
Thalidomide—Dermatitis—Gliclazide—type 2 diabetes mellitus	2.86e-05	0.000211	CcSEcCtD
Thalidomide—Diarrhoea—Valsartan—type 2 diabetes mellitus	2.86e-05	0.00021	CcSEcCtD
Thalidomide—Urticaria—Irbesartan—type 2 diabetes mellitus	2.85e-05	0.00021	CcSEcCtD
Thalidomide—Shock—Ramipril—type 2 diabetes mellitus	2.85e-05	0.00021	CcSEcCtD
Thalidomide—Headache—Gliclazide—type 2 diabetes mellitus	2.85e-05	0.00021	CcSEcCtD
Thalidomide—Nervous system disorder—Ramipril—type 2 diabetes mellitus	2.84e-05	0.000209	CcSEcCtD
Thalidomide—Abdominal pain—Irbesartan—type 2 diabetes mellitus	2.84e-05	0.000209	CcSEcCtD
Thalidomide—Body temperature increased—Irbesartan—type 2 diabetes mellitus	2.84e-05	0.000209	CcSEcCtD
Thalidomide—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	2.84e-05	0.000209	CcSEcCtD
Thalidomide—Tachycardia—Ramipril—type 2 diabetes mellitus	2.83e-05	0.000208	CcSEcCtD
Thalidomide—Diarrhoea—Orlistat—type 2 diabetes mellitus	2.82e-05	0.000208	CcSEcCtD
Thalidomide—Skin disorder—Ramipril—type 2 diabetes mellitus	2.81e-05	0.000207	CcSEcCtD
Thalidomide—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	2.8e-05	0.000206	CcSEcCtD
Thalidomide—Feeling abnormal—Losartan—type 2 diabetes mellitus	2.78e-05	0.000205	CcSEcCtD
Thalidomide—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	2.76e-05	0.000203	CcSEcCtD
Thalidomide—Dizziness—Valsartan—type 2 diabetes mellitus	2.76e-05	0.000203	CcSEcCtD
Thalidomide—Anorexia—Ramipril—type 2 diabetes mellitus	2.76e-05	0.000203	CcSEcCtD
Thalidomide—Dizziness—Orlistat—type 2 diabetes mellitus	2.73e-05	0.000201	CcSEcCtD
Thalidomide—Asthenia—Metformin—type 2 diabetes mellitus	2.73e-05	0.000201	CcSEcCtD
Thalidomide—Hypotension—Ramipril—type 2 diabetes mellitus	2.71e-05	0.000199	CcSEcCtD
Thalidomide—Nausea—Gliclazide—type 2 diabetes mellitus	2.7e-05	0.000199	CcSEcCtD
Thalidomide—Pruritus—Metformin—type 2 diabetes mellitus	2.69e-05	0.000198	CcSEcCtD
Thalidomide—Urticaria—Losartan—type 2 diabetes mellitus	2.68e-05	0.000197	CcSEcCtD
Thalidomide—Abdominal pain—Losartan—type 2 diabetes mellitus	2.67e-05	0.000196	CcSEcCtD
Thalidomide—Body temperature increased—Losartan—type 2 diabetes mellitus	2.67e-05	0.000196	CcSEcCtD
Thalidomide—Vomiting—Valsartan—type 2 diabetes mellitus	2.66e-05	0.000195	CcSEcCtD
Thalidomide—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	2.65e-05	0.000195	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	2.64e-05	0.000194	CcSEcCtD
Thalidomide—Rash—Valsartan—type 2 diabetes mellitus	2.63e-05	0.000194	CcSEcCtD
Thalidomide—Dermatitis—Valsartan—type 2 diabetes mellitus	2.63e-05	0.000194	CcSEcCtD
Thalidomide—Vomiting—Orlistat—type 2 diabetes mellitus	2.62e-05	0.000193	CcSEcCtD
Thalidomide—Insomnia—Ramipril—type 2 diabetes mellitus	2.62e-05	0.000193	CcSEcCtD
Thalidomide—Headache—Valsartan—type 2 diabetes mellitus	2.62e-05	0.000193	CcSEcCtD
Thalidomide—Diarrhoea—Metformin—type 2 diabetes mellitus	2.6e-05	0.000191	CcSEcCtD
Thalidomide—Rash—Orlistat—type 2 diabetes mellitus	2.6e-05	0.000191	CcSEcCtD
Thalidomide—Paraesthesia—Ramipril—type 2 diabetes mellitus	2.6e-05	0.000191	CcSEcCtD
Thalidomide—Dermatitis—Orlistat—type 2 diabetes mellitus	2.6e-05	0.000191	CcSEcCtD
Thalidomide—Headache—Orlistat—type 2 diabetes mellitus	2.59e-05	0.00019	CcSEcCtD
Thalidomide—Dyspnoea—Ramipril—type 2 diabetes mellitus	2.58e-05	0.00019	CcSEcCtD
Thalidomide—Asthenia—Irbesartan—type 2 diabetes mellitus	2.58e-05	0.000189	CcSEcCtD
Thalidomide—Somnolence—Ramipril—type 2 diabetes mellitus	2.58e-05	0.000189	CcSEcCtD
Thalidomide—Dyspepsia—Ramipril—type 2 diabetes mellitus	2.55e-05	0.000188	CcSEcCtD
Thalidomide—Pruritus—Irbesartan—type 2 diabetes mellitus	2.54e-05	0.000187	CcSEcCtD
Thalidomide—Decreased appetite—Ramipril—type 2 diabetes mellitus	2.52e-05	0.000185	CcSEcCtD
Thalidomide—Dizziness—Metformin—type 2 diabetes mellitus	2.52e-05	0.000185	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	2.5e-05	0.000184	CcSEcCtD
Thalidomide—Fatigue—Ramipril—type 2 diabetes mellitus	2.5e-05	0.000184	CcSEcCtD
Thalidomide—Hypersensitivity—Losartan—type 2 diabetes mellitus	2.49e-05	0.000183	CcSEcCtD
Thalidomide—Nausea—Valsartan—type 2 diabetes mellitus	2.48e-05	0.000183	CcSEcCtD
Thalidomide—Constipation—Ramipril—type 2 diabetes mellitus	2.48e-05	0.000182	CcSEcCtD
Thalidomide—Diarrhoea—Irbesartan—type 2 diabetes mellitus	2.46e-05	0.000181	CcSEcCtD
Thalidomide—Nausea—Orlistat—type 2 diabetes mellitus	2.45e-05	0.00018	CcSEcCtD
Thalidomide—Asthenia—Losartan—type 2 diabetes mellitus	2.42e-05	0.000178	CcSEcCtD
Thalidomide—Vomiting—Metformin—type 2 diabetes mellitus	2.42e-05	0.000178	CcSEcCtD
Thalidomide—Rash—Metformin—type 2 diabetes mellitus	2.4e-05	0.000176	CcSEcCtD
Thalidomide—Dermatitis—Metformin—type 2 diabetes mellitus	2.4e-05	0.000176	CcSEcCtD
Thalidomide—Pruritus—Losartan—type 2 diabetes mellitus	2.39e-05	0.000176	CcSEcCtD
Thalidomide—Feeling abnormal—Ramipril—type 2 diabetes mellitus	2.39e-05	0.000176	CcSEcCtD
Thalidomide—Headache—Metformin—type 2 diabetes mellitus	2.38e-05	0.000175	CcSEcCtD
Thalidomide—Dizziness—Irbesartan—type 2 diabetes mellitus	2.37e-05	0.000175	CcSEcCtD
Thalidomide—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	2.37e-05	0.000174	CcSEcCtD
Thalidomide—Diarrhoea—Losartan—type 2 diabetes mellitus	2.31e-05	0.00017	CcSEcCtD
Thalidomide—Urticaria—Ramipril—type 2 diabetes mellitus	2.3e-05	0.000169	CcSEcCtD
Thalidomide—Abdominal pain—Ramipril—type 2 diabetes mellitus	2.29e-05	0.000168	CcSEcCtD
Thalidomide—Body temperature increased—Ramipril—type 2 diabetes mellitus	2.29e-05	0.000168	CcSEcCtD
Thalidomide—Vomiting—Irbesartan—type 2 diabetes mellitus	2.28e-05	0.000168	CcSEcCtD
Thalidomide—Rash—Irbesartan—type 2 diabetes mellitus	2.26e-05	0.000167	CcSEcCtD
Thalidomide—Dermatitis—Irbesartan—type 2 diabetes mellitus	2.26e-05	0.000166	CcSEcCtD
Thalidomide—Nausea—Metformin—type 2 diabetes mellitus	2.26e-05	0.000166	CcSEcCtD
Thalidomide—Headache—Irbesartan—type 2 diabetes mellitus	2.25e-05	0.000165	CcSEcCtD
Thalidomide—Dizziness—Losartan—type 2 diabetes mellitus	2.23e-05	0.000164	CcSEcCtD
Thalidomide—Vomiting—Losartan—type 2 diabetes mellitus	2.15e-05	0.000158	CcSEcCtD
Thalidomide—Hypersensitivity—Ramipril—type 2 diabetes mellitus	2.13e-05	0.000157	CcSEcCtD
Thalidomide—Nausea—Irbesartan—type 2 diabetes mellitus	2.13e-05	0.000157	CcSEcCtD
Thalidomide—Rash—Losartan—type 2 diabetes mellitus	2.13e-05	0.000157	CcSEcCtD
Thalidomide—Dermatitis—Losartan—type 2 diabetes mellitus	2.13e-05	0.000157	CcSEcCtD
Thalidomide—Headache—Losartan—type 2 diabetes mellitus	2.12e-05	0.000156	CcSEcCtD
Thalidomide—Asthenia—Ramipril—type 2 diabetes mellitus	2.08e-05	0.000153	CcSEcCtD
Thalidomide—Pruritus—Ramipril—type 2 diabetes mellitus	2.05e-05	0.000151	CcSEcCtD
Thalidomide—Nausea—Losartan—type 2 diabetes mellitus	2.01e-05	0.000148	CcSEcCtD
Thalidomide—Diarrhoea—Ramipril—type 2 diabetes mellitus	1.98e-05	0.000146	CcSEcCtD
Thalidomide—Dizziness—Ramipril—type 2 diabetes mellitus	1.92e-05	0.000141	CcSEcCtD
Thalidomide—Vomiting—Ramipril—type 2 diabetes mellitus	1.84e-05	0.000135	CcSEcCtD
Thalidomide—Rash—Ramipril—type 2 diabetes mellitus	1.83e-05	0.000134	CcSEcCtD
Thalidomide—Dermatitis—Ramipril—type 2 diabetes mellitus	1.83e-05	0.000134	CcSEcCtD
Thalidomide—Headache—Ramipril—type 2 diabetes mellitus	1.81e-05	0.000134	CcSEcCtD
Thalidomide—Nausea—Ramipril—type 2 diabetes mellitus	1.72e-05	0.000127	CcSEcCtD
Thalidomide—CYP2E1—Metabolism—CAT—type 2 diabetes mellitus	2.19e-06	2.29e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CAT—type 2 diabetes mellitus	2.19e-06	2.28e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CALM1—type 2 diabetes mellitus	2.17e-06	2.26e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—type 2 diabetes mellitus	2.16e-06	2.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—LPL—type 2 diabetes mellitus	2.16e-06	2.25e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—type 2 diabetes mellitus	2.15e-06	2.25e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RELA—type 2 diabetes mellitus	2.15e-06	2.24e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOA1—type 2 diabetes mellitus	2.14e-06	2.23e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOB—type 2 diabetes mellitus	2.13e-06	2.22e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOB—type 2 diabetes mellitus	2.12e-06	2.21e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ADCY5—type 2 diabetes mellitus	2.11e-06	2.2e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—type 2 diabetes mellitus	2.11e-06	2.2e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP2E1—type 2 diabetes mellitus	2.11e-06	2.2e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	2.11e-06	2.2e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GPX1—type 2 diabetes mellitus	2.11e-06	2.2e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GNB3—type 2 diabetes mellitus	2.1e-06	2.19e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.1e-06	2.19e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PSMD6—type 2 diabetes mellitus	2.1e-06	2.19e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SREBF1—type 2 diabetes mellitus	2.1e-06	2.19e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SNAP25—type 2 diabetes mellitus	2.1e-06	2.19e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC2A2—type 2 diabetes mellitus	2.1e-06	2.19e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HMOX1—type 2 diabetes mellitus	2.09e-06	2.18e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC2A1—type 2 diabetes mellitus	2.08e-06	2.17e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP1A2—type 2 diabetes mellitus	2.08e-06	2.17e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTM1—type 2 diabetes mellitus	2.07e-06	2.16e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CAT—type 2 diabetes mellitus	2.07e-06	2.15e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTM1—type 2 diabetes mellitus	2.07e-06	2.15e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CTGF—type 2 diabetes mellitus	2.06e-06	2.15e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTR—type 2 diabetes mellitus	2.05e-06	2.14e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CPT1A—type 2 diabetes mellitus	2.05e-06	2.14e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CD36—type 2 diabetes mellitus	2.05e-06	2.14e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMGCR—type 2 diabetes mellitus	2.04e-06	2.13e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.04e-06	2.13e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP3A4—type 2 diabetes mellitus	2.03e-06	2.12e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—LPL—type 2 diabetes mellitus	2.03e-06	2.12e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—LPL—type 2 diabetes mellitus	2.03e-06	2.11e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPP2CA—type 2 diabetes mellitus	2.02e-06	2.11e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	2.02e-06	2.11e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	2.01e-06	2.1e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NAMPT—type 2 diabetes mellitus	2.01e-06	2.1e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—type 2 diabetes mellitus	2.01e-06	2.1e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOB—type 2 diabetes mellitus	2.01e-06	2.09e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	2e-06	2.09e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LIPC—type 2 diabetes mellitus	2e-06	2.09e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HBA1—type 2 diabetes mellitus	2e-06	2.09e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GCK—type 2 diabetes mellitus	2e-06	2.09e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADRA2A—type 2 diabetes mellitus	2e-06	2.09e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GCG—type 2 diabetes mellitus	2e-06	2.08e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC2A4—type 2 diabetes mellitus	2e-06	2.08e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP11A1—type 2 diabetes mellitus	1.99e-06	2.07e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ADCY5—type 2 diabetes mellitus	1.99e-06	2.07e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—type 2 diabetes mellitus	1.98e-06	2.07e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ADCY5—type 2 diabetes mellitus	1.98e-06	2.07e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GPX1—type 2 diabetes mellitus	1.98e-06	2.07e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GPX1—type 2 diabetes mellitus	1.98e-06	2.06e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC9A1—type 2 diabetes mellitus	1.95e-06	2.04e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTM1—type 2 diabetes mellitus	1.95e-06	2.03e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—INS—type 2 diabetes mellitus	1.95e-06	2.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—type 2 diabetes mellitus	1.94e-06	2.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.94e-06	2.02e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CETP—type 2 diabetes mellitus	1.93e-06	2.01e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CD36—type 2 diabetes mellitus	1.93e-06	2.01e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.93e-06	2.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IRS1—type 2 diabetes mellitus	1.93e-06	2.01e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CD36—type 2 diabetes mellitus	1.93e-06	2.01e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP2E1—type 2 diabetes mellitus	1.92e-06	2e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—LPL—type 2 diabetes mellitus	1.92e-06	2e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARA—type 2 diabetes mellitus	1.91e-06	1.99e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.91e-06	1.99e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPP2CA—type 2 diabetes mellitus	1.9e-06	1.98e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP1A2—type 2 diabetes mellitus	1.9e-06	1.98e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC2A1—type 2 diabetes mellitus	1.9e-06	1.98e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ADCY5—type 2 diabetes mellitus	1.87e-06	1.96e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GPX1—type 2 diabetes mellitus	1.87e-06	1.95e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—type 2 diabetes mellitus	1.85e-06	1.93e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP3A4—type 2 diabetes mellitus	1.85e-06	1.93e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AGT—type 2 diabetes mellitus	1.85e-06	1.93e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—INS—type 2 diabetes mellitus	1.85e-06	1.92e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	1.84e-06	1.92e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.83e-06	1.91e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—type 2 diabetes mellitus	1.83e-06	1.91e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—type 2 diabetes mellitus	1.83e-06	1.9e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GCG—type 2 diabetes mellitus	1.82e-06	1.9e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC2A4—type 2 diabetes mellitus	1.82e-06	1.9e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CD36—type 2 diabetes mellitus	1.82e-06	1.9e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CALM1—type 2 diabetes mellitus	1.82e-06	1.89e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.81e-06	1.89e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—type 2 diabetes mellitus	1.81e-06	1.89e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	1.8e-06	1.88e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.8e-06	1.87e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SNAP25—type 2 diabetes mellitus	1.79e-06	1.87e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SREBF1—type 2 diabetes mellitus	1.79e-06	1.87e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PSMD6—type 2 diabetes mellitus	1.79e-06	1.87e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARA—type 2 diabetes mellitus	1.79e-06	1.87e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARA—type 2 diabetes mellitus	1.79e-06	1.87e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOA1—type 2 diabetes mellitus	1.79e-06	1.86e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—type 2 diabetes mellitus	1.78e-06	1.86e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT2—type 2 diabetes mellitus	1.78e-06	1.86e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.78e-06	1.86e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CTGF—type 2 diabetes mellitus	1.76e-06	1.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—type 2 diabetes mellitus	1.76e-06	1.83e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	1.75e-06	1.82e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AGT—type 2 diabetes mellitus	1.74e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AGT—type 2 diabetes mellitus	1.73e-06	1.81e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.73e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—type 2 diabetes mellitus	1.72e-06	1.8e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	1.72e-06	1.8e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.72e-06	1.8e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GNB3—type 2 diabetes mellitus	1.72e-06	1.8e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMOX1—type 2 diabetes mellitus	1.71e-06	1.79e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—type 2 diabetes mellitus	1.71e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CALM1—type 2 diabetes mellitus	1.71e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	1.71e-06	1.78e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.71e-06	1.78e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—type 2 diabetes mellitus	1.71e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CALM1—type 2 diabetes mellitus	1.71e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—type 2 diabetes mellitus	1.7e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—type 2 diabetes mellitus	1.7e-06	1.77e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SERPINE1—type 2 diabetes mellitus	1.69e-06	1.77e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARA—type 2 diabetes mellitus	1.69e-06	1.76e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CAT—type 2 diabetes mellitus	1.69e-06	1.76e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SRC—type 2 diabetes mellitus	1.69e-06	1.76e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOA1—type 2 diabetes mellitus	1.68e-06	1.76e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOA1—type 2 diabetes mellitus	1.68e-06	1.75e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.64e-06	1.71e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	1.64e-06	1.71e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOB—type 2 diabetes mellitus	1.64e-06	1.71e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AGT—type 2 diabetes mellitus	1.64e-06	1.71e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—type 2 diabetes mellitus	1.62e-06	1.69e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	1.62e-06	1.69e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—type 2 diabetes mellitus	1.62e-06	1.69e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3R1—type 2 diabetes mellitus	1.62e-06	1.69e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—type 2 diabetes mellitus	1.62e-06	1.69e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CALM1—type 2 diabetes mellitus	1.61e-06	1.68e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—type 2 diabetes mellitus	1.61e-06	1.67e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTM1—type 2 diabetes mellitus	1.6e-06	1.67e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.59e-06	1.66e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOA1—type 2 diabetes mellitus	1.59e-06	1.66e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	1.58e-06	1.65e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—type 2 diabetes mellitus	1.58e-06	1.64e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	1.57e-06	1.64e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	1.57e-06	1.64e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.57e-06	1.64e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LPL—type 2 diabetes mellitus	1.57e-06	1.63e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	1.56e-06	1.63e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—type 2 diabetes mellitus	1.56e-06	1.63e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.56e-06	1.63e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	1.56e-06	1.62e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	1.56e-06	1.62e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—INS—type 2 diabetes mellitus	1.55e-06	1.61e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	1.54e-06	1.61e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ADCY5—type 2 diabetes mellitus	1.53e-06	1.6e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GPX1—type 2 diabetes mellitus	1.53e-06	1.59e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.51e-06	1.57e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—type 2 diabetes mellitus	1.5e-06	1.56e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	1.5e-06	1.56e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CD36—type 2 diabetes mellitus	1.49e-06	1.55e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—type 2 diabetes mellitus	1.48e-06	1.55e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	1.48e-06	1.54e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.48e-06	1.54e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPP2CA—type 2 diabetes mellitus	1.47e-06	1.53e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	1.46e-06	1.52e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—INS—type 2 diabetes mellitus	1.45e-06	1.52e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	1.45e-06	1.51e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	1.43e-06	1.49e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—type 2 diabetes mellitus	1.42e-06	1.48e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—type 2 diabetes mellitus	1.41e-06	1.47e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	1.4e-06	1.46e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—type 2 diabetes mellitus	1.4e-06	1.46e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	1.39e-06	1.45e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARA—type 2 diabetes mellitus	1.38e-06	1.44e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—INS—type 2 diabetes mellitus	1.37e-06	1.43e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	1.36e-06	1.42e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—type 2 diabetes mellitus	1.36e-06	1.41e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.36e-06	1.41e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.34e-06	1.4e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	1.34e-06	1.4e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	1.34e-06	1.4e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AGT—type 2 diabetes mellitus	1.34e-06	1.4e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	1.34e-06	1.39e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—type 2 diabetes mellitus	1.33e-06	1.39e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	1.33e-06	1.39e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CALM1—type 2 diabetes mellitus	1.32e-06	1.37e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	1.32e-06	1.37e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—type 2 diabetes mellitus	1.31e-06	1.37e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOA1—type 2 diabetes mellitus	1.3e-06	1.35e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	1.29e-06	1.34e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	1.28e-06	1.33e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.28e-06	1.33e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—type 2 diabetes mellitus	1.28e-06	1.33e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	1.27e-06	1.33e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	1.27e-06	1.33e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	1.26e-06	1.32e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—type 2 diabetes mellitus	1.26e-06	1.31e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	1.24e-06	1.3e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	1.22e-06	1.27e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	1.22e-06	1.27e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.2e-06	1.25e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—type 2 diabetes mellitus	1.2e-06	1.25e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	1.2e-06	1.25e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.2e-06	1.25e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	1.2e-06	1.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SRC—type 2 diabetes mellitus	1.2e-06	1.25e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	1.2e-06	1.25e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	1.19e-06	1.24e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	1.18e-06	1.23e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—type 2 diabetes mellitus	1.17e-06	1.22e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	1.16e-06	1.21e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	1.16e-06	1.21e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	1.15e-06	1.19e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—type 2 diabetes mellitus	1.14e-06	1.19e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.14e-06	1.19e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—INS—type 2 diabetes mellitus	1.12e-06	1.17e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.11e-06	1.15e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—type 2 diabetes mellitus	1.1e-06	1.15e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	1.1e-06	1.15e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	1.08e-06	1.12e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—type 2 diabetes mellitus	1.07e-06	1.12e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—type 2 diabetes mellitus	1.05e-06	1.09e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.05e-06	1.09e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	1.04e-06	1.09e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	1.04e-06	1.09e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—type 2 diabetes mellitus	1.03e-06	1.07e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	1.03e-06	1.07e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	1.02e-06	1.07e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	1.02e-06	1.07e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	1.01e-06	1.06e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3R1—type 2 diabetes mellitus	9.84e-07	1.03e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—type 2 diabetes mellitus	9.84e-07	1.03e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	9.38e-07	9.78e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—type 2 diabetes mellitus	9e-07	9.39e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	8.97e-07	9.36e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	8.97e-07	9.36e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	8.92e-07	9.3e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	8.74e-07	9.12e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	8.21e-07	8.56e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—type 2 diabetes mellitus	8.06e-07	8.41e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	8.02e-07	8.36e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—type 2 diabetes mellitus	7.85e-07	8.18e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	7.67e-07	8e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	7.67e-07	8e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—type 2 diabetes mellitus	7.44e-07	7.76e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	7.01e-07	7.31e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—type 2 diabetes mellitus	6.23e-07	6.5e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—type 2 diabetes mellitus	5.86e-07	6.12e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	5.85e-07	6.1e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—type 2 diabetes mellitus	5.53e-07	5.77e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—type 2 diabetes mellitus	4.52e-07	4.72e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	4.12e-07	4.3e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	3.52e-07	3.68e-06	CbGpPWpGaD
